| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8aa526ab8413daf73be707d2d370b9e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0f4f8190960626ec922a1f03bcd4aba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2505e2d4282599f321673bca8c60109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c5066a61a728eb8370e97e52837ae66 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2003-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b410e28be12fb79ef4bd1f536ffd47f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7fddabcf3f35870651845cb7b52fbc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f081b738184f3b228a19fa253751097 |
| publicationDate |
2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03103634-A1 |
| titleOfInvention |
Sustained release oral dosage forms of gabapentin |
| abstract |
The present invention relates to sustained release oral dosage forms of gabapentin and at least one rate controlling polymer, and a process for the preparation of the sustained release oral dosage forms, and a process for the preparation thereof. The sustained release tablet includes gabapentin or a pharmaceutically acceptable salt or hydrates thereof and at least one rate-controlling polymer such that the tablet provides therapeutically effective plasma levels of gabapentin for a period of up to about 12 hours. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005077332-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005011666-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006077492-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8795725-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008004001-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005099674-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011151708-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8906412-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008004001-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007128495-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007128495-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006113568-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006113568-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005077332-A3 |
| priorityDate |
2002-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |